Immunotherapy in Melanoma | Specialty

Dr. Grob on the Tolerability and Efficacy of Ipilimumab in Melanoma

August 24th 2017

Jean Jacques Grob, MD, PhD, professor of dermatology at the Hospital de la Timone, discusses the tolerability and efficacy of ipilimumab (Yervoy) for melanoma.

Andtbacka Discusses Long-Term Data and Next Steps With T-VEC in Melanoma

August 22nd 2017

Robert Andtbacka, MD, discusses the long-term results for T-VEC in melanoma and the remaining challenges with the oncolytic immunotherapy.

Dr. Wilson on Choosing Between BRAF/MEK Therapies for Patients With Melanoma

August 16th 2017

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.

RT Options Evolving in Oligometastatic Lung Cancer Landscape and Beyond

August 14th 2017

Billy W. Loo Jr, MD, PhD, discusses the advancements in radiation therapy options for patients with lung cancer, how SABR has improved outcomes for patients, and the intriguing combinations being explored with RT and immunotherapy.

Expert Discusses Long-Term Dabrafenib/Trametinib Data in Melanoma

August 10th 2017

Georgina V. Long, BSc, PhD, MBBS, discusses recent data with the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Stein on Targeted Therapies for Melanoma

August 4th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at NYU Langone Medical Center, discusses targeted therapies for patients with melanoma.

Dr. Meehan on Importance of IHC Testing in Melanoma

July 31st 2017

Shane A. Meehan, MD, associate professor, Ronald O. Perelman Department of Dermatology, associate professor, Department of Pathology, director of the Dermatopathology Fellowship Training Program, and director of the Dermatopathology Section at New York University Langone Medical Center, discusses the importance of immunohistochemistry (IHC) testing in melanoma.

Dr. Berman on Evolving Role of Surgery in Melanoma

July 31st 2017

Russell Berman, MD, division chief of Surgical Oncology at NYU Langone Medical Center, NYU Langone School of Medicine, shares insight on the evolving role of surgery in patients with melanoma.

Dr. Stein Discusses Skin-Related AEs With Melanoma Treatment

July 28th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.

Dr. Shapiro on Surgical Advancements in Field of Melanoma

July 28th 2017

Richard L. Shapiro, MD, associate professor, Department of Surgery, New York University Langone Medical Center, discusses recent advancements related to surgery in the field of melanoma.

Dr. Pavlick on Adjuvant Immunotherapy in High-risk Melanoma

July 27th 2017

Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.

Dr. Wilson on Long-term Data With Dabrafenib Plus Trametinib in Melanoma

July 27th 2017

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.

Amid Molecular Diagnostic Advances, IHC Retains Significance in Melanoma

July 25th 2017

Shane A. Meehan, MD, discusses the continued importance of IHC testing in melanoma, even with the emergence of novel molecular assays.

FDA Approves Ipilimumab for Pediatric Melanoma

July 24th 2017

The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma.

Expert Shares Optimism on Surgical Advances in Melanoma

July 24th 2017

Russell Berman, MD, discusses ongoing surgical advances in the treatment of melanoma.

Avelumab Recommended for EU Approval for Merkel Cell Carcinoma

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of avelumab (Bavencio) for adults with metastatic Merkel cell carcinoma, according to Pfizer and Merck, the codevelopers of the PD-L1 inhibitor.

Surgical and Systemic Techniques Evolving for Melanoma Patients With Brain Mets

July 20th 2017

Douglas Kondziolka, MD, provides insight on some of the technical advancements in treating brain metastases in patients with melanoma.

Novel Therapy Partners Emerge in Melanoma Research

July 18th 2017

A novel combination therapy aimed at 2 processes implicated in NRAS-mutant melanoma has displayed promising activity in preclinical investigations, signaling an avenue of exploration for a new therapeutic approach for patients who currently have few options.

Unmet Needs in Kidney Cancer

July 17th 2017

Kidney Cancer: Non-Clear Cell Histology

July 17th 2017